X0708 D LIVE 0002159983 Vimy Pharmaceuticals Inc. 2 BLOOR STREET WEST SUITE 2002 TORONTO A6 ONTARIO, CANADA M4W1J5 416-254-4774 ONTARIO, CANADA None None Corporation true 2024 David John Suchon 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Executive Officer Director Chief Executive Officer Farris Smith 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Executive Officer Director President and Chair Darryl Firsten 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Director Riccardo Trecroce 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Director Christopher Burkett 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Director Pharmaceuticals Decline to Disclose 06b false 2026-10-22 false true true The Issuer sold subscription receipts, which will be converted into shares of the Issuer without consideration upon the closing of the transaction. 0 Beacon Securities US Limited 000306613 Beacon Securities Limited None 66 Wellington Street West Suite 4050 Toronto A6 ONTARIO, CANADA M5K1H1 true 278174 278174 0 The total offering amount was $390,000 in Canadian dollars. The U.S. dollar value above is based on the Federal Reserve exchange rate on October 22, 2026, of $1.4020 CAD per USD. false 2 10237 true 0 Consists of an $8,345 cash fee and 3,900 stock options, each representing 3% of subscription receipts sold in the offering; total option value estimated at $1,892 using good faith Black-Scholes valuation on 11/6/26. CAD converted to USD at the rate above. 0 false Vimy Pharmaceuticals Inc. /s/ David Suchon David Suchon Chief Executive Officer 2026-11-06